Plain-English translation of NCT06375044 on ClinicalTrials.gov β Β· Source last updated Β· Translation generated Β· How we translate trials
Phase 1 β Testing in a small group (usually 20β80 people) to find a safe dose and watch for side effects.
This is one of the first times this treatment has been tested in people.
This is an early-stage trial testing a new medication called , which works by activating your immune system to fight multiple myeloma cells. The study is designed for patients whose cancer has returned or stopped responding to standard treatments. Researchers will carefully monitor your safety, how your body handles the medication, and whether it helps slow or shrink your cancer.
Multiple myeloma can become resistant to currently available treatments, leaving patients with limited options. This trial explores whether this new approach of triggering the immune system in a specific way might help patients whose cancer no longer responds to standard therapies.
You likely qualify ifβ¦
You likely don't qualify ifβ¦
You would receive the medication by infusion at a clinic or hospital setting. The trial has two parts: in the first part, researchers gradually increase doses to find the safest level, and in the second part, they test that optimal dose. You would continue receiving the medication until your cancer stops responding, you experience intolerable side effects, or the trial ends. Throughout, your doctors will monitor you closely with blood tests, scans, and regular check-ins to track how the treatment is working and any side effects.
AI-generated summary from trial data Β· Jul 12, 2026 Β· Not medical advice
United States